Glycoconjugate vaccines

D Pace - Expert opinion on biological therapy, 2013 - Taylor & Francis
Introduction: The global disease burden of serious bacterial infections is caused mainly by
Haemophilus influenzae type b (Hib), Streptococcus pneumoniae and Neisseria …

Review on the immunogenicity and safety of PCV-13 in infants and toddlers

MC Nunes, SA Madhi - Expert review of vaccines, 2011 - Taylor & Francis
Pneumococcal polysaccharide–protein conjugate vaccines (PCVs) generally protect against
vaccine-serotype-specific pneumococcal disease. Additional serotypes included in the new …

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)[prevenar 13®]

ST Duggan - Drugs, 2010 - Springer
The pneumococcal polysaccharide conjugate vaccine Prevenar 13®(PCV13) comprises 13
capsular Streptococcus pneumoniae polysaccharide serotypes that are individually …

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents

GL Plosker - Pediatric Drugs, 2013 - Springer
The 13-valent pneumococcal conjugate vaccine (Prevenar 13®; Prevnar 13®)[PCV13]
includes 13 serotype-specific polysaccharides of Streptococcus pneumoniae conjugated …

Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults

RA Gladstone, JM Jefferies, SN Faust… - Expert review of …, 2012 - Taylor & Francis
Pneumococcal disease remains a global problem despite the availability of effective
conjugate vaccines. The 13-valent pneumococcal conjugate vaccine (PCV13) extends the …

2012 antigen review for the New Zealand national immunisation schedule: Meningococcal B and C

H Petousis-Harris, P Carter, N Turner, M Nowlan - 2014 - researchspace.auckland.ac.nz
Neisseria meningitidis is the causative agent of meningococcal disease. The organism is
only found in humans and is a commensal carried in the nasopharynx of approximately 10 …